A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

This article is protected by copyright. All rights reserved.
PMID: 29453787 [PubMed - as supplied by publisher]

Source: Pigment Cell and Melanoma Research - February 17, 2018 Category: Cytology Authors: Mehnert JM, Silk AW, Wen Y, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS Tags: Pigment Cell Melanoma Res Source Type: research